Diagnostic and Prognostic Impact of Progesterone Receptor Immunohistochemistry: A Study Evaluating More Than 16,000 Tumors
Progesterone receptor (PR) is a member of the nuclear/steroid hormone receptor family of ligand-dependent transcription factors. It plays an important role in reproduction and mammary gland development and has various tissue-specific effects in nonreproductive organs. In diagnostic pathology, positi...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Analytical Cellular Pathology |
| Online Access: | http://dx.doi.org/10.1155/2022/6412148 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563083964317696 |
|---|---|
| author | Florian Viehweger Lisa-Marie Tinger David Dum Natalia Gorbokon Anne Menz Ria Uhlig Franziska Büscheck Andreas M. Luebke Claudia Hube-Magg Andrea Hinsch Doris Höflmayer Christoph Fraune Patrick Lebok Sören Weidemann Maximilian Lennartz Frank Jacobsen Till S. Clauditz Rainer Krech Till Krech Andreas H. Marx Ronald Simon Eike Burandt Stefan Steurer Guido Sauter Sarah Minner Christian Bernreuther |
| author_facet | Florian Viehweger Lisa-Marie Tinger David Dum Natalia Gorbokon Anne Menz Ria Uhlig Franziska Büscheck Andreas M. Luebke Claudia Hube-Magg Andrea Hinsch Doris Höflmayer Christoph Fraune Patrick Lebok Sören Weidemann Maximilian Lennartz Frank Jacobsen Till S. Clauditz Rainer Krech Till Krech Andreas H. Marx Ronald Simon Eike Burandt Stefan Steurer Guido Sauter Sarah Minner Christian Bernreuther |
| author_sort | Florian Viehweger |
| collection | DOAJ |
| description | Progesterone receptor (PR) is a member of the nuclear/steroid hormone receptor family of ligand-dependent transcription factors. It plays an important role in reproduction and mammary gland development and has various tissue-specific effects in nonreproductive organs. In diagnostic pathology, positive PR immunostaining is used to support a diagnosis of breast or gynecologic origin in a tumor. In this study, the expression of PR was analyzed by immunohistochemistry in 18,176 (interpretable: 16,445) samples from 147 different tumor types and subtypes in a tissue microarray format. PR immunostaining was detected in 57.4% of breast tumors, 28.6% of other gynecological tumors, and 1.8% of nongynecological and nonmammary tumors. Among the group of nongynecological and nonmammary tumors, particularly high rates of PR positivity were seen in neuroendocrine tumors (54.3%) and neuroendocrine carcinomas (35.7%) of the pancreas. A comparison with clinico-pathological parameters showed that reduced PR immunostaining was significantly associated with adverse histopathological and clinical features in breast carcinoma, endometrioid endometrial carcinoma, and pancreatic neuroendocrine tumors. In summary, our analysis of 147 different tumor types for PR immunostaining provides a ranking list of tumor entities according to their prevalence of PR positivity, helps to better understand the diagnostic utility of PR, and highlights the distinct PR positivity among neuroendocrine neoplasms of pancreatic origin. |
| format | Article |
| id | doaj-art-647ccbf0fe5044e5b9d0820406d3e277 |
| institution | Kabale University |
| issn | 2210-7185 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Analytical Cellular Pathology |
| spelling | doaj-art-647ccbf0fe5044e5b9d0820406d3e2772025-02-03T01:21:05ZengWileyAnalytical Cellular Pathology2210-71852022-01-01202210.1155/2022/6412148Diagnostic and Prognostic Impact of Progesterone Receptor Immunohistochemistry: A Study Evaluating More Than 16,000 TumorsFlorian Viehweger0Lisa-Marie Tinger1David Dum2Natalia Gorbokon3Anne Menz4Ria Uhlig5Franziska Büscheck6Andreas M. Luebke7Claudia Hube-Magg8Andrea Hinsch9Doris Höflmayer10Christoph Fraune11Patrick Lebok12Sören Weidemann13Maximilian Lennartz14Frank Jacobsen15Till S. Clauditz16Rainer Krech17Till Krech18Andreas H. Marx19Ronald Simon20Eike Burandt21Stefan Steurer22Guido Sauter23Sarah Minner24Christian Bernreuther25Institute of PathologyInstitute of PathologyInstitute of PathologyInstitute of PathologyInstitute of PathologyInstitute of PathologyInstitute of PathologyInstitute of PathologyInstitute of PathologyInstitute of PathologyInstitute of PathologyInstitute of PathologyInstitute of PathologyInstitute of PathologyInstitute of PathologyInstitute of PathologyInstitute of PathologyInstitute of PathologyInstitute of PathologyInstitute of PathologyInstitute of PathologyInstitute of PathologyInstitute of PathologyInstitute of PathologyInstitute of PathologyInstitute of PathologyProgesterone receptor (PR) is a member of the nuclear/steroid hormone receptor family of ligand-dependent transcription factors. It plays an important role in reproduction and mammary gland development and has various tissue-specific effects in nonreproductive organs. In diagnostic pathology, positive PR immunostaining is used to support a diagnosis of breast or gynecologic origin in a tumor. In this study, the expression of PR was analyzed by immunohistochemistry in 18,176 (interpretable: 16,445) samples from 147 different tumor types and subtypes in a tissue microarray format. PR immunostaining was detected in 57.4% of breast tumors, 28.6% of other gynecological tumors, and 1.8% of nongynecological and nonmammary tumors. Among the group of nongynecological and nonmammary tumors, particularly high rates of PR positivity were seen in neuroendocrine tumors (54.3%) and neuroendocrine carcinomas (35.7%) of the pancreas. A comparison with clinico-pathological parameters showed that reduced PR immunostaining was significantly associated with adverse histopathological and clinical features in breast carcinoma, endometrioid endometrial carcinoma, and pancreatic neuroendocrine tumors. In summary, our analysis of 147 different tumor types for PR immunostaining provides a ranking list of tumor entities according to their prevalence of PR positivity, helps to better understand the diagnostic utility of PR, and highlights the distinct PR positivity among neuroendocrine neoplasms of pancreatic origin.http://dx.doi.org/10.1155/2022/6412148 |
| spellingShingle | Florian Viehweger Lisa-Marie Tinger David Dum Natalia Gorbokon Anne Menz Ria Uhlig Franziska Büscheck Andreas M. Luebke Claudia Hube-Magg Andrea Hinsch Doris Höflmayer Christoph Fraune Patrick Lebok Sören Weidemann Maximilian Lennartz Frank Jacobsen Till S. Clauditz Rainer Krech Till Krech Andreas H. Marx Ronald Simon Eike Burandt Stefan Steurer Guido Sauter Sarah Minner Christian Bernreuther Diagnostic and Prognostic Impact of Progesterone Receptor Immunohistochemistry: A Study Evaluating More Than 16,000 Tumors Analytical Cellular Pathology |
| title | Diagnostic and Prognostic Impact of Progesterone Receptor Immunohistochemistry: A Study Evaluating More Than 16,000 Tumors |
| title_full | Diagnostic and Prognostic Impact of Progesterone Receptor Immunohistochemistry: A Study Evaluating More Than 16,000 Tumors |
| title_fullStr | Diagnostic and Prognostic Impact of Progesterone Receptor Immunohistochemistry: A Study Evaluating More Than 16,000 Tumors |
| title_full_unstemmed | Diagnostic and Prognostic Impact of Progesterone Receptor Immunohistochemistry: A Study Evaluating More Than 16,000 Tumors |
| title_short | Diagnostic and Prognostic Impact of Progesterone Receptor Immunohistochemistry: A Study Evaluating More Than 16,000 Tumors |
| title_sort | diagnostic and prognostic impact of progesterone receptor immunohistochemistry a study evaluating more than 16 000 tumors |
| url | http://dx.doi.org/10.1155/2022/6412148 |
| work_keys_str_mv | AT florianviehweger diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT lisamarietinger diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT daviddum diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT nataliagorbokon diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT annemenz diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT riauhlig diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT franziskabuscheck diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT andreasmluebke diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT claudiahubemagg diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT andreahinsch diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT dorishoflmayer diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT christophfraune diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT patricklebok diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT sorenweidemann diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT maximilianlennartz diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT frankjacobsen diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT tillsclauditz diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT rainerkrech diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT tillkrech diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT andreashmarx diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT ronaldsimon diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT eikeburandt diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT stefansteurer diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT guidosauter diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT sarahminner diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors AT christianbernreuther diagnosticandprognosticimpactofprogesteronereceptorimmunohistochemistryastudyevaluatingmorethan16000tumors |